PL1902141T3 - Kompozycje o działaniu trombolitycznym zawierające ADAMTS13 - Google Patents
Kompozycje o działaniu trombolitycznym zawierające ADAMTS13Info
- Publication number
- PL1902141T3 PL1902141T3 PL06754405T PL06754405T PL1902141T3 PL 1902141 T3 PL1902141 T3 PL 1902141T3 PL 06754405 T PL06754405 T PL 06754405T PL 06754405 T PL06754405 T PL 06754405T PL 1902141 T3 PL1902141 T3 PL 1902141T3
- Authority
- PL
- Poland
- Prior art keywords
- adamts13
- thrombus
- compositions
- thrombolytic activity
- disintegrating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US69192705P | 2005-06-17 | 2005-06-17 | |
US72932305P | 2005-10-21 | 2005-10-21 | |
US77126506P | 2006-02-07 | 2006-02-07 | |
EP06754405A EP1902141B1 (en) | 2005-06-17 | 2006-06-16 | Adamts13-comprising compositions having thrombolytic activity |
PCT/EP2006/005800 WO2006133955A1 (en) | 2005-06-17 | 2006-06-16 | Adamts13-comprising compositions having thrombolytic activity |
Publications (1)
Publication Number | Publication Date |
---|---|
PL1902141T3 true PL1902141T3 (pl) | 2012-12-31 |
Family
ID=36956096
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL06754405T PL1902141T3 (pl) | 2005-06-17 | 2006-06-16 | Kompozycje o działaniu trombolitycznym zawierające ADAMTS13 |
Country Status (10)
Country | Link |
---|---|
US (4) | US20070015703A1 (pl) |
EP (1) | EP1902141B1 (pl) |
AT (1) | ATE544866T1 (pl) |
AU (1) | AU2006257073B2 (pl) |
CA (1) | CA2606351C (pl) |
DK (1) | DK1902141T3 (pl) |
ES (1) | ES2382104T3 (pl) |
HK (1) | HK1118579A1 (pl) |
PL (1) | PL1902141T3 (pl) |
WO (1) | WO2006133955A1 (pl) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7083786B2 (en) | 1997-04-03 | 2006-08-01 | Jensenius Jens Chr | MASP-2, a complement-fixing enzyme, and uses for it |
US8840893B2 (en) | 2004-06-10 | 2014-09-23 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
US7919094B2 (en) * | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
PL1902141T3 (pl) | 2005-06-17 | 2012-12-31 | Baxalta Inc | Kompozycje o działaniu trombolitycznym zawierające ADAMTS13 |
FR2918375B1 (fr) * | 2007-07-05 | 2009-10-16 | Lab Francais Du Fractionnement | Utilisation d'un support de chromatographie pour reduire la quantite d'adamts13 dans une solution derivee du plasma |
US20090317375A1 (en) * | 2008-05-12 | 2009-12-24 | Immune Disease Institute, Inc. | Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction |
EP3495488A1 (en) * | 2008-10-27 | 2019-06-12 | Baxalta GmbH | Models of thrombotic thrombocytopenic purpura and methods of use thereof |
EP3388529A1 (en) * | 2008-12-05 | 2018-10-17 | Baxalta GmbH | Methods of measuring adamts13-mediated in vivo cleavage of von willebrand factor and uses thereof |
JP5411582B2 (ja) * | 2009-06-02 | 2014-02-12 | 一般財団法人化学及血清療法研究所 | Adamts13による細胞移植増強補助剤 |
US8945895B2 (en) | 2009-07-31 | 2015-02-03 | Baxter International Inc. | Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof |
US8580554B2 (en) | 2009-07-31 | 2013-11-12 | Baxter International Inc. | Method of producing a polypeptide or virus of interest in a continuous cell culture |
CN102573792B (zh) | 2009-09-21 | 2014-10-15 | 巴克斯特国际公司 | 稳定化的液体和冻干的adamts13制剂 |
JP5911804B2 (ja) * | 2009-10-16 | 2016-04-27 | オメロス コーポレーション | Masp−2依存性の補体活性化を阻害することによって播種性血管内凝固を処置するための方法 |
KR20220044616A (ko) * | 2011-04-08 | 2022-04-08 | 유니버시티 오브 레스터 | Masp-2 의존적 보체 활성화와 관련된 질병을 치료하는 방법 |
US9644035B2 (en) | 2011-04-08 | 2017-05-09 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
AU2013203062C1 (en) * | 2013-03-15 | 2018-06-28 | Takeda Pharmaceutical Company Limited | Subcutaneous administration of adamts13 |
GB201410693D0 (en) | 2014-06-16 | 2014-07-30 | Univ Southampton | Splicing modulation |
KR102620328B1 (ko) | 2014-10-03 | 2024-01-02 | 콜드스프링하버러보러토리 | 핵 유전자 산출량의 표적화 증강 |
CN105991563B (zh) * | 2015-02-05 | 2020-07-03 | 阿里巴巴集团控股有限公司 | 一种保护敏感数据安全的方法、装置及三方服务系统 |
US10639307B2 (en) | 2015-05-15 | 2020-05-05 | Children's Medical Center Corporation | Methods relating to the diagnosis and treatment of preeclampsia comprising administration of ADAMTS13 polypeptides |
KR20220105174A (ko) | 2015-10-09 | 2022-07-26 | 유니버시티 오브 사우스앰톤 | 유전자 발현의 조절 및 탈조절된 단백질 발현의 스크리닝 |
WO2017106377A1 (en) | 2015-12-14 | 2017-06-22 | Cold Spring Harbor Laboratory | Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome |
US11096956B2 (en) | 2015-12-14 | 2021-08-24 | Stoke Therapeutics, Inc. | Antisense oligomers and uses thereof |
EP3401685B1 (en) | 2016-01-08 | 2021-12-01 | Kyoto University | Diagnostic method and medicine comprising adamts13 as main ingredient |
EA201990373A1 (ru) * | 2016-08-04 | 2019-07-31 | Баксалта Инкорпорэйтед | Применение adamts13 для лечения, уменьшения интенсивности и/или предупреждения вазоокклюзивного криза при серповидноклеточной анемии, остром повреждении легкого и/или остром респираторном дистресс-синдроме |
SG10202108375XA (en) | 2017-08-25 | 2021-09-29 | Stoke Therapeutics Inc | Antisense oligomers for treatment of conditions and diseases |
US20220339266A1 (en) * | 2019-10-04 | 2022-10-27 | The Children's Medical Center Corporation | Adamts13 treatment to enhance graft survival |
JP2023521658A (ja) | 2020-04-02 | 2023-05-25 | 武田薬品工業株式会社 | Adamts13バリアント、組成物、及びその使用 |
US20230287410A1 (en) | 2020-05-11 | 2023-09-14 | Stoke Therapeutics, Inc. | Opa1 antisense oligomers for treatment of conditions and diseases |
US20230201319A1 (en) | 2020-05-22 | 2023-06-29 | Takeda Pharmaceutical Company Limited | Adamts13 compositions and methods for treating and diagnosing complications of coronavirus disease |
EP4249594A1 (en) * | 2020-11-18 | 2023-09-27 | Green Cross Corporation | Adamts13 variant having increased escaping rate or activity against autoantibody |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5082218A (pl) * | 1973-11-10 | 1975-07-03 | ||
US4791138A (en) * | 1983-12-14 | 1988-12-13 | The Upjohn Company | Method for treating or preventing deep vein thrombosis using lipoxygenase inhibitors |
NZ517184A (en) * | 1999-07-13 | 2004-02-27 | Bolder Biotechnology Inc | Immunoglobulin fusion proteins that are cytokines or growth factors joined to an Immunoglobulin domain |
US6926894B2 (en) * | 2000-11-22 | 2005-08-09 | Baxter Aktiengesellschaft | Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV |
JP2003284570A (ja) | 2001-04-25 | 2003-10-07 | Chemo Sero Therapeut Res Inst | フォンビルブラント因子(vWF)切断酵素 |
WO2003016492A2 (en) * | 2001-08-16 | 2003-02-27 | The Regents Of The University Of Michigan | Adamts13 genes and proteins and variants, and uses thereof |
US20030073115A1 (en) * | 2002-09-16 | 2003-04-17 | Shyam Ramakrishnan | Regulation of human galanin receptor-like g protein coupled receptor |
US7763430B2 (en) * | 2003-04-22 | 2010-07-27 | Baxter International Inc. | Diagnostic assay for anti-von Willebrand Factor cleaving protease (ADAMTS13) antibodies |
EP1568782A1 (de) * | 2004-02-25 | 2005-08-31 | Clemens Bockmeyer | Diagnose und Therapie von ADAMTS-13 assoziierten Erkrankungen |
PL1902141T3 (pl) | 2005-06-17 | 2012-12-31 | Baxalta Inc | Kompozycje o działaniu trombolitycznym zawierające ADAMTS13 |
-
2006
- 2006-06-16 PL PL06754405T patent/PL1902141T3/pl unknown
- 2006-06-16 CA CA2606351A patent/CA2606351C/en not_active Expired - Fee Related
- 2006-06-16 DK DK06754405.6T patent/DK1902141T3/da active
- 2006-06-16 AU AU2006257073A patent/AU2006257073B2/en active Active
- 2006-06-16 EP EP06754405A patent/EP1902141B1/en active Active
- 2006-06-16 US US11/454,615 patent/US20070015703A1/en not_active Abandoned
- 2006-06-16 WO PCT/EP2006/005800 patent/WO2006133955A1/en not_active Application Discontinuation
- 2006-06-16 ES ES06754405T patent/ES2382104T3/es active Active
- 2006-06-16 AT AT06754405T patent/ATE544866T1/de active
-
2008
- 2008-09-05 HK HK08109912.8A patent/HK1118579A1/xx unknown
-
2013
- 2013-01-22 US US13/747,307 patent/US10233436B2/en active Active
-
2019
- 2019-01-30 US US16/262,180 patent/US11124787B2/en active Active
-
2021
- 2021-09-17 US US17/478,520 patent/US20220002703A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20130136732A1 (en) | 2013-05-30 |
AU2006257073A1 (en) | 2006-12-21 |
US20070015703A1 (en) | 2007-01-18 |
ES2382104T3 (es) | 2012-06-05 |
WO2006133955A8 (en) | 2007-11-29 |
AU2006257073B2 (en) | 2011-08-04 |
US11124787B2 (en) | 2021-09-21 |
EP1902141B1 (en) | 2012-02-08 |
ATE544866T1 (de) | 2012-02-15 |
CA2606351C (en) | 2016-12-13 |
DK1902141T3 (da) | 2012-05-07 |
US10233436B2 (en) | 2019-03-19 |
HK1118579A1 (en) | 2009-02-13 |
US20190161746A1 (en) | 2019-05-30 |
CA2606351A1 (en) | 2006-12-21 |
WO2006133955A1 (en) | 2006-12-21 |
EP1902141A1 (en) | 2008-03-26 |
US20220002703A1 (en) | 2022-01-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1118579A1 (en) | Adamts13-comprising compositions having thrombolytic activity | |
MX2012004551A (es) | Nuevas composiciones para prevenir y/o tratar trastornos de almacenamiento lisosomal. | |
WO2006124874A3 (en) | Inhibitors of b-raf kinase | |
TN2010000122A1 (en) | Compounds and compositions as modulators of gpr119 activity | |
PL2134704T3 (pl) | Związki i kompozycje pełniące rolę modulatorów aktywności GPR119 | |
MX2009000285A (es) | Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas. | |
WO2005105780A3 (en) | Compositions useful as inhibitors of rock and other protein kinases | |
TW200604168A (en) | Azaindoles useful as inhibitors of rock and other protein kinases | |
MX2009005527A (es) | Metodos para el tratamiento de hipercolesterolemia. | |
TW200716091A (en) | New therapeutic combinations for the treatment or prevention of psychotic disorders | |
TW200637522A (en) | Skin treatment articles and methods | |
MY145070A (en) | Imidazolothiazole compounds for the treatment of disease | |
WO2007087068A3 (en) | Inhibitors of tyrosine kinases and uses thereof | |
MY191349A (en) | New pharmaceutical compositions for the treatment of hyper-proliferative disorders | |
WO2008148074A3 (en) | Inhibitors of mtor and methods of treatment using same | |
WO2007062093A3 (en) | Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor | |
WO2008017025A3 (en) | Combination therapy | |
TW200716204A (en) | Pharmaceutical composition | |
WO2007087151A3 (en) | Combination of ache inhibitor and 5-ht6 antagonist for the treatment of cognitive dysfunction | |
MX2008015775A (es) | Compuestos y composiciones para tratamiento de cancer. | |
UA96926C2 (ru) | Применение sdf-1 для лечения и/или профилактики неврологических заболеваний | |
TW200716153A (en) | Mitotic kinesin inhibitors and methods of use thereof | |
WO2006116185A3 (en) | Methods for the treatment of multiple myeloma | |
WO2007041388A3 (en) | Prevention and treatment of hearing disorders | |
WO2006128740A3 (en) | Anti-vascular methods and therapies employing lysyl oxidase inhibitors |